Also available in Persian — نسخه فارسی EN فا
❓ Unknown

Groundbreaking Psilocin Trial Shows Positive Results for Binge Eating Disorder

17h ago September 16, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

A groundbreaking trial conducted by Swinburne University of Technology and Entropy Neurodynamics tested IV-infused psilocin for binge eating disorder, showing improvements in all participants. This trial represents a significant advancement in mental health treatment. While not directly related to Iran, it highlights global trends in mental health research that could influence Iranian healthcare policies.

🔍 Quick Context Guide
💡 Bottom Line: The trial's success may pave the way for innovative mental health treatments globally, including in Iran.

👥 Key Players

Swinburne University of Technology MENTIONED
Research Institution
"A leading institution in Australia known for its innovative research, potentially influencing global mental health treatment approaches."
Entropy Neurodynamics MENTIONED
Neuroscience Company
"A company focused on neurotherapeutics, contributing to advancements in treatment for mental health disorders."

📰 What Happened

A clinical trial conducted by Swinburne University and Entropy Neurodynamics tested IV-infused psilocin for treating binge eating disorder, resulting in positive outcomes for all participants.

  • This is the world's first trial of its kind for binge eating disorder.
  • All participants showed improvements, indicating potential for new treatment options.

💡 Why It Matters

🇮🇷 For Iran: This trial could inspire Iranian healthcare policymakers to explore alternative mental health treatments, especially given the rising mental health issues in the country.
🌍 Regional: If successful, it may lead to broader acceptance of psychedelic treatments in the Middle East, challenging traditional views on mental health.
🌐 International: The positive results could encourage further research and investment in psychedelic therapies worldwide, influencing global mental health strategies.

📚 Background

Psilocin is a psychedelic compound derived from mushrooms, and recent studies have shown promise in treating various mental health disorders, including depression and anxiety.

Psychedelic therapy Mental health treatment advancements
📡 Source: NEUTRAL
📊 Confidence: 70%
The information comes from a research-focused perspective, providing factual data without apparent bias.

Swinburne University of Technology and Entropy Neurodynamics' world's first IV-infused psilocin binge-eating disorder trial has led to improvements in all participants.

🏷️ Entities Mentioned

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →